PMID- 35547468
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1559-3258 (Print)
IS  - 1559-3258 (Electronic)
IS  - 1559-3258 (Linking)
VI  - 20
IP  - 2
DP  - 2022 Apr-Jun
TI  - Screening of Prognostic Biomarkers for Stereotactic Body Radiation Therapy in 
      Primary Liver Cancer.
PG  - 15593258221097589
LID - 10.1177/15593258221097589 [doi]
LID - 15593258221097589
AB  - OBJECTIVE: So far there are still no effective immediate-early markers for 
      assessing the efficacy of Stereotactic Body Radiation Therapy (SBRT). To find 
      effective biomarkers for accurate assessment of the efficacy of SBRT in patients 
      with primary liver cancer, we conducted this study including retrospective part 
      and prospective part. MATERIAL AND METHODS: 589 patients with primary liver 
      cancer were included at Ruikang Hospital affiliated to Guangxi Medical University 
      from January 2012 to December 2018. Follow-up was conducted, clinical information 
      and a total of 17 patients with 51 blood samples (before SBRT, before discharge 
      and 2 months after SBRT) were collected. mRNAs profiles on 2 patients with 6 
      blood samples were detected by high-throughput sequencing, followed by qPCR 
      verification on 15 patients with 45 blood samples. RESULTS: The commonly used 
      serum biomarkers such as AFP, CEA, and CA125 shown low prognostic value in 
      distinguishing survival group and death group, indicated by low AUC (less than 
      .7) and Youden indexes (less than .5). Based on high-throughput sequencing of 
      test group and qPCR detection of another verification group, we found 16 
      up-regulated and 12 downregulated genes after SBRT. Among them, ADIPOR1 and EPB42 
      showed significantly different between effective and ineffective group after 
      SBRT, ROC suggested that based on the optimal threshold of .5838, ADIPOR1 shown a 
      sensitivity of 100% and a specificity of 83.33% to distinguish effective from 
      ineffective group. And EPB42 had a sensitivity of 75% and a specificity of 100% 
      at the optimal threshold of 1.3817. In addition, GSEA showed that high expression 
      of ADIPOR1 was mainly related to Mismatch repair, Circadian rhythm, Protein 
      processing in endoplasmic reticulum, DNA replication, and Fanconi anemia 
      pathways. CONCLUSION: ADIPOR1 in whole blood is a promising candidate to act as 
      prognostic biomarker for predication of SBRT outcomes in primary liver cancer 
      patients.
CI  - (c) The Author(s) 2022.
FAU - Liang, Zhenzhen
AU  - Liang Z
AUID- ORCID: 0000-0002-4069-2625
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
AD  - NHC Key Laboratory of Radiobiology (Jilin University), Changchun, Jilin, China. 
      RINGGOLD: 26453
FAU - Xue, Chang
AU  - Xue C
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
FAU - Chen, Qing
AU  - Chen Q
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
FAU - Li, Mengke
AU  - Li M
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
FAU - Li, Guanghui
AU  - Li G
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
FAU - Feng, Hao
AU  - Feng H
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
FAU - Liu, Yi
AU  - Liu Y
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
FAU - Liu, Xiaodong
AU  - Liu X
AUID- ORCID: 0000-0002-6879-990X
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
AD  - South Zhejiang Institute of Radiation Medicine and Nuclear Technology, Wenzhou, 
      Zhejiang, China. RINGGOLD: 26453
AD  - Key Laboratory of Watershed Science and Health of Zhejiang Province, Wenzhou 
      Medical University, Wenzhou, Zhejiang, China. RINGGOLD: 26453
FAU - Ma, Shumei
AU  - Ma S
AUID- ORCID: 0000-0002-9167-4582
AD  - School of Public Health and Management, Wenzhou Medical University, Wenzhou, 
      Zhejiang, China. RINGGOLD: 12510
AD  - South Zhejiang Institute of Radiation Medicine and Nuclear Technology, Wenzhou, 
      Zhejiang, China. RINGGOLD: 26453
AD  - Key Laboratory of Watershed Science and Health of Zhejiang Province, Wenzhou 
      Medical University, Wenzhou, Zhejiang, China. RINGGOLD: 26453
LA  - eng
PT  - Journal Article
DEP - 20220506
PL  - United States
TA  - Dose Response
JT  - Dose-response : a publication of International Hormesis Society
JID - 101308899
PMC - PMC9083052
OTO - NOTNLM
OT  - biomarkers
OT  - liver cancer
OT  - prognosis
OT  - stereotactic body radiation therapy
COIS- Declaration of Conflicting Interests: The author declared the following potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/14 06:01
PMCR- 2022/05/06
CRDT- 2022/05/13 11:13
PHST- 2022/02/05 00:00 [received]
PHST- 2022/04/10 00:00 [accepted]
PHST- 2022/05/13 11:13 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/14 06:01 [medline]
PHST- 2022/05/06 00:00 [pmc-release]
AID - 10.1177_15593258221097589 [pii]
AID - 10.1177/15593258221097589 [doi]
PST - epublish
SO  - Dose Response. 2022 May 6;20(2):15593258221097589. doi: 
      10.1177/15593258221097589. eCollection 2022 Apr-Jun.